#USA #Chicago #lipid nanoparticles #Genprex #diabetes

Genprex Unveils Innovative Research at the 2025 ADA Scientific Sessions

In a significant breakthrough for diabetes treatment, Genprex, Inc., a leading clinical-stage gene therapy firm, has unveiled promising research at the 2025 American Diabetes Association (ADA) 85th Scientific Sessions held in Chicago. The focus of their study is on GPX-002, a novel diabetes gene therapy candidate, which has shown potential in preclinical trials using a non-viral lipid nanoparticle (LNP) delivery system. This research not only represents advancement in diabetes care but also highlights the possibility of repeated dosing, a crucial factor in managing Type 1 diabetes.

Key Findings from GD-002 Research

CEO Ryan Confer emphasized the pivotal nature of this research, stating, "We believe we are the first and only company conducting this type of work utilizing lipid nanoparticles for direct infusion into the pancreatic duct. The potential for repeat dosing could be critical in Type 1 diabetes treatment."

The research included a poster presentation titled "Selecting Lipid Nanoparticles for Transfection of Islets of Langerhans Cells" that spotlighted some exciting results. In this study, nine uniquely designed lipid nanoparticles using patented LipexSil® lipids were assessed for their efficacy in transfecting isolated mouse islet cells. Intriguingly, two of these nanoparticles exhibited exceptional efficiency, paving the way for enhanced delivery of therapeutic payloads directly to pancreatic tissues.

The Importance of Non-Viral Delivery Systems

The significance of using a non-viral delivery system cannot be understated. Conventional gene therapy techniques often rely on viral vectors for delivery, which may provoke immune responses or require immunosuppressive protocols. However, the LNPs used in this research demonstrated minimal toxicity and a robust capacity to reach and effectively transfect pancreatic cells without triggering such responses. For instance, a specific LNP carrying the Luciferase mRNA exhibited a 100-fold increase in activity within pancreatic tissues compared to other organs, confirming its precision and targeting capability.

Dr. Mark Berger, Genprex's Chief Medical Officer, remarked on these advancements, stating, "Our approach shows not just the feasibility but the potential for significant improvement in delivering gene therapies for diabetes. The efficiency and specificity of our LNPs could substantially alter how diabetes is treated in the future."

Future Directions in Diabetes Gene Therapy

Genprex aims to extend its groundbreaking research with further clinical studies. The company is currently exploring ways to optimize the next generation of gene constructs via non-viral systems alongside its familiar AAV vector approach. This dual strategy could broaden the therapeutic window and enhance the effectiveness of treatment protocols for both Type 1 and Type 2 diabetes.

About GPX-002

GPX-002 is a gene therapy designed to transform pancreatic alpha cells into beta-like cells capable of producing insulin. This transformational approach could offer a critical advantage, especially for patients with a robust immune response to typical beta-cell therapies. Preliminary studies with GPX-002 have demonstrated the ability to regulate blood glucose levels effectively in animal models, indicating a promising direction for human applications.

Genprex continues to pursue partnerships with world-class institutions and maintains an innovative pipeline focused on gene therapies aimed at addressing unmet medical needs.

As Genprex moves forward, the implications of this research resonate beyond diabetes; they could potentially reshape the landscape of gene therapy for various diseases.

Investors and interested parties are encouraged to stay updated by visiting Genprex's official website for the latest news and progress on their revolutionary therapies.